WHAT IS CLAIMED IS:

1. A formulation comprising water, (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt and a sufficient amount of a water sequestering agent to inhibit decomposition of (6-(5-fluoro-2-(3,4,5-trimethoxyphenyl-amino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt during granulation, tablet formation and/or storage, wherein said formulation, after drying, has a bulk density sufficient to form tablets having a hardness in the range of about 6 kp to about 30 kp.

2. The formulation of Claim 1, wherein after drying the formulation has a bulk density of between about 0.35 to about 0.65 g/mL.

3. The formulation of Claim 1, wherein the water sequestering agent is selected from the group consisting of starch, magnesium sulfate, calcium chloride, silica gel, and kaolin.

4. The formulation of Claim 3, wherein the water sequestering agent is starch.

5. The formulation of Claim 4, wherein the starch is partially pregelatinized.

6. The formulation of Claim 5, wherein the starch is derived from Maize.

7. The formulation of Claim 1 which further comprises at least one of a filler, a lubricant, a suspending/dispersing agent, a binding agent, and a disintegrant.

8. A tablet comprising water, a therapeutically effective amount of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt and a sufficient amount of a water sequestering agent to inhibit decomposition of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt, wherein said tablet has a hardness in the range of about 6 kp to about 30 kp.

9. The tablet of Claim 8, wherein said tablet exhibits at least 75% dissolution in less than 45 minutes in an aqueous solution maintained at pH 7.4, a temperature of 37 °C +0.5 °C, and a paddle speed of 75 rpm.

10. The tablet of Claim 8 which further comprises at least one of a filler, a lubricant, a suspending/dispersing agent, a binding agent, and a disintegrant.

11. The tablet of any of Claims 8, 9 or 10, wherein the tablet comprises from greater than 25 mg to about 200 mg of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt.

12. The tablet of Claim 11, wherein the tablet comprises about 50 mg to about 100 mg of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt.

13. The tablet of Claim 12, wherein the tablet comprises about 100 mg of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt.

14. A method for formulating (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt into a formulation for tablet compression which method comprises:

a) blending (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt with starch and optionally at least one of a filler, a lubricant, a suspending/dispersing agent, a binding agent and a disintegrant, at an impellor speed sufficient to form a homogenous powder mixture having a bulk density, after drying, of about 6 kp to about 30 kp;

b) spraying between about 15 percent and about 40 percent by weight of water into the homogenous powder mixture of a) and mixing to form enlarged granules; and

c) drying the enlarged granules of b) until an LOD of between about 5% and about 11% is achieved, to provide dried granules.

15. The method of Claim 14, wherein the dried granules are sized between about 25 μm to about 900 μm in diameter.

16. The method of Claim 14 which further comprises milling the dried granules, to provide milled granules

17. The method of Claim 16, wherein the dried granules are milled so that about 90 weight percent of the milled granules have a particle size between about 25 to about 900 μm in diameter.

18. The method of Claim 17, further comprising mixing the milled granules with a lubricant until homogenous, and then tabletting the resulting formulation.

19. A wet granulating process, comprising:
    a) blending a composition comprising Compound 1 and a water sequestering agent to form a blended mixture;
    b) granulating the blended mixture of a) while adding water to form wet granules;
    c) drying the wet granules of b) at < 65 °C until an LOD of between about 5% and 11% is achieved to provide dried granules; and
    d) blending a lubricant into the dried granules of c) to provide blended granules.

20. The method of claim 19, further comprising:
    e) compressing the blended granules to form tablets.

21. A formulation comprising a therapeutically effective amount of Compound 1, a water sequestering agent, a lubricant, and about 5% to about 11% water, wherein the water sequestering agent is present in an amount sufficient to inhibit decomposition of Compound 1.

22. The formulation of claim 21, wherein the formulation has a bulk density of between about 0.35 to about 0.65 g/mL.

23. A tablet formed by compressing the wet granulated formulation of claim 21.

WHAT IS CLAIMED IS:

1. A formulation comprising water, (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt and a sufficient amount of a water sequestering agent to inhibit decomposition of (6-(5-fluoro-2-(3,4,5-trimethoxyphenyl-amino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt during granulation, tablet formation and/or storage, wherein said formulation, after drying, has a bulk density sufficient to form tablets having a hardness in the range of 6 kp to 30 kp.

2. A wet granulated formulation comprising water, a therapeutically effective amount of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt and a sufficient amount of a water sequestering agent to inhibit decomposition of (6-(5-fluoro-2-(3,4,5-trimethoxyphenyl-amino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt, wherein said wet granulated formulation, after drying, has a bulk density sufficient to form tablets having a hardness in the range of 6 kp to 30 kp.

3. The formulation of Claim 1 or 2, wherein after drying the formulation has a bulk density of between 0.35 to 0.65 g/mL.

4. The formulation of Claim 1 or 2, wherein the water sequestering agent is selected from the group consisting of starch, magnesium sulfate, calcium chloride, silica gel, and kaolin.

5. The formulation of Claim 4, wherein the water sequestering agent is starch.

6. The formulation of Claim 5, wherein the starch is partially pregelatinized.

7. The formulation of Claim 6, wherein the starch is derived from Maize.

8. The formulation of Claim 1 or 2 which further comprises at least one of a filler, a lubricant, a suspending/dispersing agent, a binding agent, and a disintegrant.

9. A tablet comprising water, a therapeutically effective amount of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt and a sufficient amount of a water sequestering agent to inhibit decomposition of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt, wherein said tablet has a hardness in the range of 6 kp to 30 kp.

10. The tablet of Claim 9, wherein said tablet exhibits at least 75% dissolution in less than 45 minutes in an aqueous solution maintained at pH 7.4, a temperature of 37 °C +0.5 °C, and a paddle speed of 75 rpm.

11. The tablet of Claim 9 which further comprises at least one of a filler, a lubricant, a suspending/dispersing agent, a binding agent, and a disintegrant.

12. The tablet of any of Claims 9, 10, or 11, wherein the tablet comprises from greater than 25 mg to 200 mg of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt.

13. The tablet of Claim 12, wherein the tablet comprises 50 mg to 100 mg of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt.

14. The tablet of Claim 13, wherein the tablet comprises 100 mg of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt.

15. A method for formulating (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt into a formulation for tablet compression which method comprises:

    a) blending (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt with starch and optionally at least one of a filler, a lubricant, a suspending/dispersing agent, a binding

agent and a disintegrant, at an impellor speed sufficient to form a homogenous powder mixture having a bulk density, after drying, of 6 kp to 30 kp;

b) spraying between 15 % and 40 % by weight of water with respect to the total weight of the powder mixture plus water and mixing to form wet granules; and

c) drying the wet granules until a loss on drying of between 5% and 11% is achieved, to provide dried granules.

16. The method of Claim 15, wherein the dried granules are sized between 25 μm to 900 μm in diameter.

17. The method of Claim 15 which further comprises milling the dried granules, to provide milled granules.

18. The method of Claim 17, wherein the dried granules are milled so that 90 weight percent of the milled granules have a particle size between 25 to 900 μm in diameter.

19. The method of Claim 18, further comprising mixing the milled granules with a lubricant until homogenous, and then tabletting the resulting formulation.

20. A wet granulating process, comprising:

a) blending a composition comprising (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt and a sufficient amount of a water sequestering agent for inhibiting decomposition of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt to form a blended mixture;

b) granulating the blended mixture of a) while adding water to form wet granules;

c) drying the wet granules of b) at below 65 °C until a loss on drying of between 5% and 11% is achieved to provide dried granules; and

d) blending a lubricant into the dried granules of c) to provide blended granules.

21. The method of claim 20, further comprising:

e) compressing the blended granules to form tablets.

22. A formulation comprising a therapeutically effective amount of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt, a water sequestering agent, a lubricant, and 5% to 11% water, wherein the water sequestering agent is present in an amount sufficient to inhibit decomposition of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino) pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt.

23. The formulation of claim 22, wherein the formulation has a bulk density of between 0.35 to 0.65 g/mL.

24. A tablet formed by compressing the wet granulated formulation of claim 22.